MediSpend and Life Sciences Subsidiary of RLDatix Merge to Form Leading Global Provider of Regulatory and Compliance SaaS Solutions for Life Sciences

New company delivers built-for-purpose, best-in-class solutions spanning the entire product lifecycle for pharmaceutical, biotech, and medical device companies

PORTSMOUTH, N.H., Sept. 2, 2025 /PRNewswire/ -- MediSpend and RLDatix Life Sciences, a subsidiary of RLDatix, today announced a definitive agreement to merge, creating a new unified company at the forefront of life sciences innovation and compliance. The new company offers the most comprehensive suite of software, data and workflow tools to support the entire lifecycle for global compliance, transparency, and sales enablement for the life sciences industry. The combined company currently serves over 300 pharmaceutical, biotech, and medical device companies worldwide.

Backed by Five Arrows (the alternative assets arm of Rothschild & Co.), Susquehanna Growth Equity, TA Associates, and Nordic Capital, the new company brings together RLD Life Sciences' expertise in providing services for pharmaceutical product development, commercialization, and distribution with robust compliance, and sales enablement alongside MediSpend's best-in-class transparency, stakeholder engagement, and data solutions supporting both commercial and clinical stakeholders.

MediSpend brings innovative technology that enables life sciences companies to grow their businesses compliantly through SaaS-based Stakeholder Engagement, Event Management, Spend Transparency, and advanced Clinical Data Document Anonymization and Redaction capabilities.

RLDatix Life Sciences contributes unmatched subject matter expertise and market-leading skills by empowering life sciences companies to master complexity, mitigate risk, and continually exceed the standards of compliance - from Government Pricing to Learning and Development.

This strategic integration empowers pharmaceutical and life sciences companies to accelerate innovation, ensure regulatory integrity, and bring high-quality healthcare solutions to market more efficiently and ethically, while adhering to the highest compliance standards.

"This combination builds on our commitment to delivering innovative software, services, and support to life sciences companies across the globe," said Michael Allelunas, CEO of the new company. "Together, we combine our purpose-built platform of solutions to streamline global compliance, drive operational efficiency, and unlock new opportunities for our customers."

Leigh Powell, Chairman of the new company, added: "This merger represents a powerful alignment of mission and capability. We are excited to bring together our technologies, teams, and customers to provide the go-forward partner of choice for the life sciences industry. Our shared focus on innovation and client success will continue to guide us."

Clients and partners can expect uninterrupted service, increased investment in product development, and a clear commitment to a seamless integration experience. The company will continue to operate under both brand names in the near term, with a long-term vision to unify under a new common name which will be announced in the coming months.

About MediSpend
MediSpend's leading solutions empower life sciences companies to grow their business compliantly through top-rated solutions and client services. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York, Pennsylvania and the Netherlands. Visit MediSpend online at www.medispend.com.

About RLDatix Life Sciences
RLDatix Life Sciences, a subsidiary of RLDatix, is a leading provider of comprehensive solutions in the life sciences industry. Formed through the integration of Porzio Life Sciences, iContracts, and iCoachFirst, RLDatix Life Sciences offers cutting-edge compliance solutions, and strategic coaching and training services. The company is committed to driving excellence and innovation within the life sciences industry. Visit www.rldatixlifesciences.com to learn more.

About Five Arrows
Five Arrows is the alternative assets arm of Rothschild & Co and has over €29 billion in assets under management, with offices in Paris, London, New York, Los Angeles, San Francisco, and Luxembourg.

With more than €10 billion of assets under management, the corporate private equity business of Five Arrows is focused on investing in companies with strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology–enabled business services, and healthcare.

For more information, visit: www.rothschildandco.com/en/five-arrows/corporate-private-equity

About SGE
Susquehanna Growth Equity (SGE) is an entrepreneur-centric growth equity fund with flexible capital and time horizons. SGE is exclusively focused on growth-stage software, services, internet, and information services companies. The firm has invested in over $5 billion in 100+ market-leading technology and services companies over the last 19 years and has portfolio companies across the US, Canada, Europe, and Israel. SGE is backed by a unique and patient source of capital, enabling the firm to give entrepreneurs and management teams freedom and flexibility to manage growth. To learn more, please visit www.sgep.com.

About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five core sectors - technology, business services, financial services, healthcare and consumer. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

About Nordic Capital
Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 30 billion in over 150 investments. The committed capital is principally provided by global institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. For more information see www.nordiccapital.com.

"Nordic Capital" refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital's entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as "Nordic Capital Advisors".

Media Contact
Seth Houston
[email protected]

SOURCE MediSpend